Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast
Report Link: https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html
The oncology precision medicine market is valued at USD 130 billion in 2023 growing at a CAGR of 8.93% during the forecast period 2023-2035.
Cancer is globally acknowledged as one of the most lethal diseases, characterized by its widespread occurrence and high mortality rates. As per data from the World Health Organization, in 2020 alone, there were approximately 20 million new cases of cancer and 10 million cancer-related deaths reported annually, with projections indicating a staggering 60% increase in these figures by the year 2040. The rise in cancer prevalence and pathogenesis is attributed to various factors including alcohol consumption, obesity, viral infections, exposure to radiation and chemicals. Traditional treatment methods for cancer, such as surgery, radiation therapy, and chemotherapy, are commonly employed. Additionally, there are complementary or alternative therapeutic approaches like hormone therapy, immunotherapy, and nanotherapy. However, these treatments have shown limitations in addressing the intrinsic genetic abnormalities underlying cancer, which can stem from specific mutations in oncogenes, tumor suppressor genes, and DNA repair genes. To overcome the limitations of existing treatments, the concept of precision medicine, also known as personalized medicine, has emerged. Precision medicine utilizes genomic information to develop targeted therapies tailored to individual patients. By analyzing tumor characteristics, genetic data, patient lifestyle, and environmental factors, precision medicine offers promising potential in treating cancer by moving away from a one-size-fits-all approach.
Individuals with a family history of certain cancers are at higher risk of inheriting the condition, and precision oncology enables them to undergo genetic testing to assess their risk. Early cancer screening facilitates early detection, leading to improved treatment outcomes. Notably, several precision cancer centers like MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic Cancer Center in the US provide advanced technologies and treatments tailored for patients with rare or challenging cancers. Clinical trials of oncology precision medicines have demonstrated high efficacy, leading to increased participation of volunteers and consequently expanding the patient pool in such trials. This aids researchers in making better-informed decisions regarding evaluated drugs or technologies. With ongoing research and innovation in precision medicine, there is an anticipated significant increase in the adoption of targeted drugs, thereby driving growth in the oncology precision medicine market in the foreseeable future.

Key Market Segments
Type of Cancer Targeted
?Bladder Cancer
?Blood / Hematologic Cancer
?Breast Cancer
?Cervical Cancer
?Gastrointestinal Cancer
?Head and Neck Squamous Cell Cancer
?Lung Cancer
?Skin Cancer
?Others
Route of Administration
?Oral
?Intravenous
?Others
Type of Molecule
?Small Molecules
?Biologics
Drug Class
?Kinase Inhibitors
?Enzyme Inhibitors
?Immune Checkpoint Inhibitors
?Others
Leading Drug Developers
?Merck
?Pfizer
?AstraZeneca
?Johnson $ Johnson Innovative Medicine
?Genentech
Key Geographical Regions
?North America (US, Canada)
?Europe (France, Germany, Italy, Spain and UK)
?Asia (China, Japan, Korea and India)
?Middle East and North Africa (UAE, Israel, Qatar and Rest of Middle East and North Africa)
?Latin America (Brazil, Argentina, Chile and Rest of Latin America)
Research Coverage:
?The report studies the oncology in precision market based on type of cancer targeted route of administration, type of molecule, drug class, key geographical regions.
?The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
?The report forecasts the revenue of market segments with respect to five major regions
?An overview of precision medicine, particularly in the field of oncology, is provided along with a comparison to traditional cancer medications. The process of developing oncology precision medicines is outlined, and the advantages they offer are discussed, highlighting their anticipated significance in shaping the future of personalized healthcare. Additionally, challenges associated with oncology precision medicine are addressed in this chapter.
?The report provides an overview of oncology in precision medicine, including its evolution, types, and application areas. It also covers the benefits of these procedures compared to traditional beauty treatments and the side effects associated with them. The chapter also covers the key drivers of growth, new technologies, key issues and future prospects in this field.
?Comprehensive analysis of the current landscape of oncology in precision medicine developers considering parameters such as establishment year, company size, headquarters, stage of development, approval body, approval region, drug designation, type of molecule, drug class, route of administration, dosage regimen, patient population and type of cancer targeted. Additionally, the chapter presents a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on several relevant parameters, such as stage of development, type of molecule, drug class and type of cancer targeted.
?In-depth profiles of companies offering precision medicine, focusing on company overviews, financial information (where available), portfolio, recent advancements, and informed future prospects.
?An analysis of partnerships established in this sector since 2018, covering clinical trial agreement, commercialization agreement, drug development agreement, drug development and commercialization agreement, drug distribution agreement, drug licensing agreement, manufacturing agreement, merger / acquisition, process development and manufacturing agreement, research agreement, research and development agreement, service agreement, technology utilization agreement and others.
?A thorough examination of completed or ongoing clinical trials in the field of oncology precision medicine is conducted, focusing on several key parameters including trial registration year, patient enrollment numbers, trial phase, status, target patient demographics, gender distribution, types of cancer targeted, sponsorship or collaboration types, study design characteristics, intervention models, and trial purposes. The analysis also identifies the most active sponsors or collaborators, comprising both industry and non-industry players based on their sponsorship of clinical trials. Additionally, emerging focus areas and geographical trends are explored within this clinical trial analysis.
?A case study is presented on developers of precision oncology assay kits, offering a detailed analysis across several parameters including development stage (commercialized and under development), regulatory certification and compliance, regional availability, test type, sample type, biomarker detection principle, turnaround time, cancer type targeted, and end-user demographics. Furthermore, the chapter includes insights on various assay kit developers, along with an analysis based on parameters such as establishment year, company size, and headquarters location.
?The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
Key Benefits of Buying this Report
?The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
?Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
?The report provides stakeholders with a pulse on the oncology precision medicine market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies
?AbbVie
?Anticancer Bioscience
?Astellas Pharma
?Astrazeneca
?Bayer
?Blueprint Medicines
?Bristol Myers Squibb
?Eli Lilly
?Erasca
?Genentech
?GlaxoSmithKline
?Hutchmed
?IDEAYA Biosciences
?Jiangsu Hengrui Pharmaceuticals
?Johnson & Johnson Innovative Medicine
?Merck
?Novartis
?Pfizer
?Repare Therapeutics
?Roche
?Seagen
?SpringWorks Therapeutics
?Takeda Pharmaceutical
?VERAXA Biotech GmbH
?VRise Therapeutics